Purpose: To assess differences between corneal biomechanical properties in patients with non-infectious uveitis and healthy subjects using CorVis.
Methods: 77 patients with non-infectious uveitis and 47 control subjects were recruited. Biomechanical parameters were measured: deformation amplitude (DA), A-1 length and A-2 length (L1, L2), A-1 velocity and A-2 velocity (V1, V2), peak distance (PD) and HC radius (highest concavity radius). AUC ROC and correlation between clinical variables and biomechanical properties were determined.
Results: Lower HC Radius and IOPb and higher DA and V1 was found in uveitis group. Statistical differences between cases using systemic medications and those with topical treatment were found in L1. Differences were showed between those cases with active and inactive uveitis in PD, DA, V2 and L2. The biomechanical parameter with the best discriminatory capacity of uveitis disease was HC Radius.
Conclusion: Differences in corneal biomechanical properties between non-infectious uveitis and healthy eyes were found.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09273948.2022.2108462 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anterior Segment Optical Coherence Tomography Evaluation of a Dexamethasone Intravitreal Implant in the Crystalline Lens: A Case Report.
Int Med Case Rep J
January 2025
Department of Ophthalmology, Centro Hospitalar Universitário de São João, Porto, Portugal.
Purpose: Ozurdex is a dexamethasone intravitreal implant approved for the treatment of macular edema secondary to branch or central retinal vein occlusion, non-infectious uveitis affecting the posterior segment of the eye, and diabetic macular edema.
Patients And Methods: We report a case of an accidental injection of the implant into the crystalline lens, successfully managed by surgery afterwards. The case description is supported by Anterior Segment Optical Coherence Tomography (AS-OCT) images.
Correction: Fluocinolone acetonide 0.2 µg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations.
J Ophthalmic Inflamm Infect
January 2025
Department of Ophthalmology, Pitié-Salpêtrière Hospital, Paris, France.
Incidence of non-infectious uveitis among patients with hidradenitis suppurativa.
Br J Dermatol
January 2025
Northwell, New Hyde Park, NY, USA.
Economic Burden and Cost-Effectiveness of Management of Non-Infectious Uveitis: A Systematic Review.
Ocul Immunol Inflamm
January 2025
Institute of Health Policy, Management and Evaluation, University of Toronto, Ontario, Canada.
Purpose: To evaluate the economic burden and cost-effectiveness of interventions and management of non-infectious uveitis (NIU).
Methods: A comprehensive search was conducted across Medline, Embase, and Scopus databases from inception to March 2023. Risk of bias assessments were conducted using the Joanna Briggs Institute critical appraisal tools.
Adalimumab Autoantibodies in Uveitis Patients: Do We Need Routine Drug Monitoring?
Biomedicines
December 2024
Department of Ophthalmology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
Background: Adalimumab, an anti-TNF-α biologic agent, has emerged as a principal treatment option for patients with non-infectious uveitis. The influence of adalimumab anti-drug antibodies (AAA) on the efficacy of adalimumab therapy is not yet fully understood. We aim to understand their clinical implications in the context of therapeutic drug monitoring and the factors contributing to the formation of these antibodies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!